AngioDynamics, Inc. expected to post a loss of 11 cents a share - Earnings Preview

AngioDynamics

28/09/2026 13:32

AngioDynamics, Inc. ANGO.OQ ANGO.O is expected to  show a rise in quarterly revenue when it reports  results on September 30 (estimated) for the period ending August 31 2026
The Latham New York-based  company is expected to report a 6.3% increase in revenue to $80.5 million from $75.71 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
​LSEG's mean analyst estimate for AngioDynamics, Inc. is for a loss of 11 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for AngioDynamics, Inc. is $19.50, about 25.9% above its last closing price of $15.49
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
May. 31 2026
-0.09
-0.09
-0.07
Beat
22.2
Feb. 28 2026
-0.11
-0.11
0.02
Beat
118.2
Nov. 30 2025
-0.10
-0.10
0.00
Beat
100​
Aug. 31 2025
-0.12
-0.12
-0.10
Beat
14.9
​​May. 31 2025
-0.13
-0.12
-0.03
Beat
75
Feb. 28 2025
-0.14
-0.13
0.03
Beat
123.1​
Nov. 30 2024
-0.10
-0.11
-0.04
Beat
63.6
Aug. 31 2024
-0.15
-0.15
-0.11
Beat
25
This summary was machine generated September 28 at 12:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)